Theravance Biopharma (TBPH) EBITDA (2013 - 2026)
Theravance Biopharma (TBPH) reported EBITDA of -$9.5 million for Q1 2026, up 30.2% year-over-year from -$7.3 million in Q1 2025, and down 147.39% quarter-over-quarter from $20.0 million in Q4 2025.
Theravance Biopharma (TBPH) EBITDA (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of EBITDA data on file, last reported at -$9.5 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$9.5 million, up 30.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.0 million (up 232.91% YoY), and the FY2025 annual result was $32.3 million, up 168.82% from the prior year.
- EBITDA retreated to -$9.5 million in Q1 2026 per TBPH's latest filing, from $20.0 million in the prior quarter.
- Over five years, EBITDA peaked at $916.6 million in Q3 2022 and troughed at -$26.0 million in Q1 2022.
- A 5-year average of $48.1 million and a median of -$9.5 million in 2026 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA surged 2696.33% in 2022, then tumbled 100.97% in 2023.
- A 5-year view of EBITDA shows it stood at -$17.4 million in 2022, then jumped by 64.2% to -$6.2 million in 2023, then tumbled by 47.44% to -$9.2 million in 2024, then surged by 317.52% to $20.0 million in 2025, then plunged by 147.39% to -$9.5 million in 2026.
- Business Quant data shows TBPH's EBITDA at -$9.5 million in Q1 2026, $20.0 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -9.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.48 Mn |
| Dec 31, 2025 | 20.01 Mn |
| Sep 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 54.83 Mn |
| Mar 31, 2025 | -13.59 Mn |
| Dec 31, 2024 | -9.20 Mn |
| Sep 30, 2024 | -12.63 Mn |
| Jun 30, 2024 | -16.51 Mn |
| Mar 31, 2024 | -11.64 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -8.89 Mn |
| Jun 30, 2023 | -15.98 Mn |
| Mar 31, 2023 | -22.02 Mn |
| Dec 31, 2022 | -17.43 Mn |
| Sep 30, 2022 | 916.56 Mn |
| Jun 30, 2022 | -8.21 Mn |
| Mar 31, 2022 | -25.97 Mn |
| Dec 31, 2021 | -56.17 Mn |
| Sep 30, 2021 | -35.30 Mn |
| Jun 30, 2021 | -52.41 Mn |